The Effects of Individualised Short-term Sleep Restriction on Tactical Performance

March 28, 2025 updated by: José Afonso Coelho Neves

Influence Of Individualized Two Weeks Mild Sleep Restriction On Tactical Performance During Small-Sided Games In National Male Under-19 Football Players: A Randomized Trial

The goal was to evaluate the influence that chronic sleep restriction may have on football players tactical performance during small-sided games. By using a relative sleep restriction (i.e., by reducing the normal sleep duration by 15%) instead of an absolute sleep restriction (e.g., 3-4 hours), different sleep schedules were applied, according to the players individual sleep profile. It was hypothesized that the player's performance would be impaired, particularly their tactical behaviors when performing a 4x4 small-sided game format.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

An impairment on cognitive and physical performance is commonly suggested in literature. However, there is a lack of information regarding sport-specific parameters. Thus, the present study aimed to examine whether chronic sleep restriction during 9 consecutive days impairs the tactical performance of football players during small-sided games (SSGs). A total of sixteen national level male football players wore wrist actigraphy units during night sleep throughout the study. Players were randomized into two groups: intervention (IG), and control (CG). The first four days corresponded to a familiarization period, where players were informed about the study procedures and started using wrist actigraphy. Throughout the next seven consecutive days, the characterization phase of sleep players profile (i.e., baseline) was collected and analyzed. Then, players entered the intervention phase, where the IG slept 15% less than routine. During this 9-days period, players performed a 4x4 SSGs in two moments (moment 1 and moment 2) with a week interval. The SSGs were recorded using a video camera and subsequently analyzed using the Game Performance Assessment Instrument.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
16

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Portugal
      • Porto, Portugal, 4200-450
        • Faculty of Sport, University of Porto

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Soccer players classified as Tier 3, corresponding to the National Level in accordance to McKay et al. (2022), as they represented the under-19 team playing in the Portuguese National Championship 1st Division.

Exclusion Criteria:

  • 1) players with previously identified sleep disorders;
  • 2) players with injuries that prevented them from playing SSGs.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Sleep restriction
During the intervention period (i.e., 9 consecutive days), the intervention group started the sleep protocol, sleeping only the quantity of hours defined for their individual chronic partial sleep restriction (15% of usual daily sleep hours). The amount and quality of sleep obtained were daily monitored through actigraphy devices, and all the players filled in a sleep diary when they woke up. During this period, players performed the SSGs in two different moments (moment 1 and moment 2), interspersed by 4 days.
Behavioral: Sleep restriction
During the intervention period (i.e., 9 consecutive days), the intervention group started the sleep protocol, sleeping only the quantity of hours defined for their individual chronic partial sleep restriction (15% of the usual sleep time). The amount and quality of sleep obtained were daily monitored through actigraphy devices, and all the players filled in a sleep diary when they woke up. During this period, players performed the SSGs in two different moments (moment 1 and moment 2), interspersed by 4 days.
No Intervention: Controls
Same intervention (i.e., soccer training and tests) as the other arm, but with no sleep restriction.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Game Performance Assessment Instrument (GPAI)
Time Frame: Applied once in week 1 and once again in week 2
According to study purposes, tactical performance was defined as the main variables. Tactical analysis was performed using the Game Performance Assessment Instrument (GPAI), a tool designed to evaluate the individual tactical behavior (Memmert & Harvey, 2008; Oslin, Mitchell, & Griffin, 1998). It consists of seven components, two of which are evaluated when the player has the ball and the remaining five when the player does not have the ball possession. For example, decisions made about what to do with the ball during the game, and motor skill execution were classified as appropriate/efficient or inappropriate/inefficient. The main index proposed by Oslin et al. (1998) was calculated: Game Performance (GP). Based on actions deemed appropriate or inappropriate, the final score can range from 0 to 100%, with higher values denoting better outcomes.
Applied once in week 1 and once again in week 2

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Sleep efficiency
Time Frame: Collected daily during the two weeks of the intervention
The objective sleep data was collected using three axial accelerometers (ActiGraph LLC wGT3X-BT, Pensacola, USA) placed on the non-dominant wrist. To analyze the wrist actigraphy data, the ActiLife LLC Pro software (v6.13.3, Pensacola, USA) was used with a sampling frequency of 50Hz and an epoch of activity counts of 60s. Sleep efficiency (SE, percentage of time in bed that was spent asleep; CV=7%) was determined using the Sadeh's algorithm.
Collected daily during the two weeks of the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
José Afonso Coelho Neves

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 1, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 31, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 23, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 28, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 4, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 4, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 28, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CEFADE 9 2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Sensitive data belonging to a club, so we only had permission to report the statistical treatment, but not sharing the IPD.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings